Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia

• Status: Completed
• Trial end date: 2007-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the protocol is to evaluate the efficacy of olanzapine compared with Aripiprazole in patients with schizophrenia.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Aripiprazole; Olanzapine

Criteria

Inclusion Criteria:

• Male or female inpatient or outpatients, ages 18-65

Exclusion Criteria:

• Participation in a clinical trial of another drug including olanzapine or aripiprazole within 30 days prior to study entry (visit 1).

• Treatment with clozapine within the past 12 months.

• Have known uncorrected narrow-angle glaucoma.

• Have a diagnosis of Parkinson's disease, dementia or related disorder